Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)

~13 mi. (Balashikha, Russia, +93 more cities)

Moscow Regional Oncological Dispensary ( Site 0812)

PD-L1 High Expression (TPS >= 1%), +1 more biomarker

Non-Small Cell Lung Carcinoma

vibostolimab/pembrolizumab MK-7684A

immunotherapy

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~13 mi. (Balashikha, Russia, +122 more cities)

Moscow Regional Oncological Dispensary-Oncology (thoracic surgery) Department №1 ( Site 1815)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~20 mi. (Moscow, Russia, +192 more cities)

Fed State Budgetary Inst "N.N. Blokhin Med Center of Oncology" MHRF

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~20 mi. (Moscow, Russia, +144 more cities)

Moscow Oncological Clinical Dispensary #1 ( Site 2619), +1 more facility

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~20 mi. (Moscow, Russia, +176 more cities)

FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 2634)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~20 mi. (Moscow, Russia, +89 more cities)

Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 1901), +2 more facilities

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~20 mi. (Moscow, Russia, +383 more cities)

Moscow Clinical Scientific Center

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~20 mi. (Moscow, Russia, +226 more cities)

Central Clinical Hospital with Polyclinic ( Site 0562), +1 more facility

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~20 mi. (Moscow, Russia, +147 more cities)

MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 0722)

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~20 mi. (Moscow, Russia, +93 more cities)

National Medical Research Centre of Oncology named after N.N. Blokhin ( Site 0865), +1 more facility

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~20 mi. (Moscow, Russia, +199 more cities)

Blokhin National Medical Oncology ( Site 0645), +2 more facilities

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~20 mi. (Moscow, Russia, +159 more cities)

FSBI ""United Hospital with Polyclinic"" of the Administrative Department of the President of the Ru, +1 more facility

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type